Clinical Trial Update: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating intermittent darolutamide treatment as part of triple therapy for metastatic hormone-sensitive prostate cancer is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy | Phase 3 | Status: RECRUITING